Investor Relations (IR) Questions: Aastrom Biosciences ASTM
Click here to return to the biotech IRQ Index
Answers received: January 2013
Capital Raising: Aastrom raised $40 million on March 9, 2012 in a preferred stock offering. More information on this can be found in our filings with the SEC.
Cash Position: As of 9/30/2012, our cash on hand was $21.1 million. We provide the investor community with an update on our cash position each quarter with the filing of our 10-K as well as on our quarterly earnings call.
Catalyst: We initiated our phase 2b clinical trial in ischemic dilated cardiomyopathy (ixCELL-DCM trial) in Q4. We expect to complete enrollment in 2013 and report data in 2014.
Cash Burn: For the 3rd quarter ended, 9/30/2012, our cash used for operations was $8 million and we project $7-8M for Q4. Consistent with our cash position reporting, we update investors on our cash burn on a quarterly basis.
Line of Credit: We do not currently have a line of credit, however we do have a $20M ATM facility in place.
Capital Raising: Aastrom raised $40 million on March 9, 2012 in a preferred stock offering. More information on this can be found in our filings with the SEC.
Cash Position: As of 9/30/2012, our cash on hand was $21.1 million. We provide the investor community with an update on our cash position each quarter with the filing of our 10-K as well as on our quarterly earnings call.
Catalyst: We initiated our phase 2b clinical trial in ischemic dilated cardiomyopathy (ixCELL-DCM trial) in Q4. We expect to complete enrollment in 2013 and report data in 2014.
Cash Burn: For the 3rd quarter ended, 9/30/2012, our cash used for operations was $8 million and we project $7-8M for Q4. Consistent with our cash position reporting, we update investors on our cash burn on a quarterly basis.
Line of Credit: We do not currently have a line of credit, however we do have a $20M ATM facility in place.
Answers received: September 2012
Capital Raising: Aastrom raised $40 million on March 9, 2012 in a preferred stock offering. More information on this can be found in our filings with the SEC.
Cash Position: As of 6/30/2012, our cash on hand was $28.6 million. We provide the investor community with an update on our cash position each quarter with the filing of our 10-Q as well as on our quarterly earnings call.
Catalyst: We plan to initiate enrollment for our phase 2b clinical trial in ischemic dilated cardiomyopathy (ixCELL-DCM trial) late Q3/early Q4. We expect to complete enrollment in the middle of 2013 and report data in mid-2014. Our phase 3 REVIVE-CLI trial, which began enrolling in May 2012, is expected to take 2 years to enroll with an additional 12 months of follow up, so data is expected in mid-2015.
Cash Burn: For the 2nd quarter ended, 6/30/2012, our cash used for operations was $8 million and we project $7-8M for Q3. Consistent with our cash position reporting, we update investors on our cash burn on a quarterly basis.
Line of Credit: We do not currently have a line of credit, however we do have a $20M ATM facility in place that was unused as of June 30, 2012.
Capital Raising: Aastrom raised $40 million on March 9, 2012 in a preferred stock offering. More information on this can be found in our filings with the SEC.
Cash Position: As of 6/30/2012, our cash on hand was $28.6 million. We provide the investor community with an update on our cash position each quarter with the filing of our 10-Q as well as on our quarterly earnings call.
Catalyst: We plan to initiate enrollment for our phase 2b clinical trial in ischemic dilated cardiomyopathy (ixCELL-DCM trial) late Q3/early Q4. We expect to complete enrollment in the middle of 2013 and report data in mid-2014. Our phase 3 REVIVE-CLI trial, which began enrolling in May 2012, is expected to take 2 years to enroll with an additional 12 months of follow up, so data is expected in mid-2015.
Cash Burn: For the 2nd quarter ended, 6/30/2012, our cash used for operations was $8 million and we project $7-8M for Q3. Consistent with our cash position reporting, we update investors on our cash burn on a quarterly basis.
Line of Credit: We do not currently have a line of credit, however we do have a $20M ATM facility in place that was unused as of June 30, 2012.
